Articles by tag: crispr-gene-editing

CRISPR gene editing: treatment of hypertriglyceridemia CTX310

CRISPR Therapeutics presented CTX310 — a one-time gene therapy that reduces triglycerides by 82% and LDL by 86%. Learn about the revolution in dyslipidemia treatment and market prospects.

CRISPR therapy VERVE-102 reduces cholesterol by 62% after injection

Journal NEJM published data on the drug VERVE-102: a single CRISPR injection (base editing) reduces LDL by 62% for 18 months without serious side effects. Learn details about the revolutionary therapy.

CRISPR in vivo reduces cholesterol by 60% in VERVE-102 study

Single infusion of VERVE-201 sustainably lowers LDL by more than 60%. Learn how CRISPR editing is changing the hypercholesterolemia therapy market. Read the analysis.